Physician profile
Divya Batra
NPI 1780896381
$10,588.46
in general payments reported to CMS, 2019-2025
47 companies · $2,363 in 2025
The $2,363 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $513 · 2021: $1,154 · 2022: $1,609 · 2023: $2,322 · 2024: $2,396 · 2025: $2,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,986 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,986.18 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,765.16 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $1,271.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,094.82 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $972.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $936.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $497.80 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.38 | 2019-2024 | Jardiance, Spiriva Respimat, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $408.85 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $356.43 | 2022-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $309.08 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $208.89 | 2021 | |
| Glaxosmithkline, LLC. | $204.96 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Janssen Pharmaceuticals, INC | $173.20 | 2019-2025 | Xarelto, Spravato |
| Kowa Pharmaceuticals America, INC. | $164.38 | 2021-2023 | Seglentis |
| Novartis Pharmaceuticals Corporation | $158.46 | 2019-2025 |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Batra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.